

Resource Summary Report

Generated by [NIF](#) on Aug 19, 2026

Fred Hutchinson Cancer Center Comparative Medicine Core Facility

RRID:SCR_022610

Type: Tool

Proper Citation

Fred Hutchinson Cancer Center Comparative Medicine Core Facility (RRID:SCR_022610)

Resource Information

URL: <https://www.fredhutch.org/en/research/shared-resources/core-facilities/comparative-medicine.html>

Proper Citation: Fred Hutchinson Cancer Center Comparative Medicine Core Facility (RRID:SCR_022610)

Description: Core teams of technicians, veterinarians, pathologists and operations specialists offer services in diagnostic and research pathology and support development and maintenance of preclinical mouse models, including mice bearing humanized immune system. Provides access to high quality technical services and immune deficient mice. Can perform individual technical services or complete entire in vivo experiments. Facilities are fully accredited by Association for Assessment and Accreditation of Laboratory Animal Care International and comply with all U.S. Department of Agriculture, Public Health Service, Washington state and local area regulations.

Synonyms: Fred Hutchinson Cancer Center Comparative Medicine Shared Resource

Resource Type: core facility, access service resource, service resource

Keywords: diagnostic and research pathology, preclinical mouse models, mice bearing humanized immune system, immune deficient mice, ABRF, USEDit, NACCSR

Availability: open

Resource Name: Fred Hutchinson Cancer Center Comparative Medicine Core Facility

Resource ID: SCR_022610

Alternate IDs: ABRF_1536

Alternate URLs: https://coremarketplace.org/RRID:SCR_022610/?citation=1

Record Creation Time: 20220802T050144+0000

Record Last Update: 20260819T044551+0000

Ratings and Alerts

No rating or validation information has been found for Fred Hutchinson Cancer Center Comparative Medicine Core Facility.

No alerts have been found for Fred Hutchinson Cancer Center Comparative Medicine Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Hagen MW, et al. (2026) The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy. *Blood advances*, 10(7), 2452.

Ramsey EL, et al. (2026) MondoA mediates transcriptional coordination between the MYC network and the integrated stress response in pancreatic cancer. *Proceedings of the National Academy of Sciences of the United States of America*, 123(10), e2524659123.

Chhan CB, et al. (2026) Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. *Cell reports. Medicine*, 7(2), 102618.

Zhang S, et al. (2026) A CD8?? co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands. *Nature communications*, 17(1), 753.

Liu Y, et al. (2026) Therapeutic scheduling of WEE1 inhibition preserves T cell function and promotes immune control of HPV+ tumors. *bioRxiv : the preprint server for biology*.

Castelli JMP, et al. (2026) In vivo production of an anti-HIV antibody in mice by non-viral gene knockin in primate hematopoietic stem and progenitor cells. *Molecular therapy : the journal of the American Society of Gene Therapy*, 34(5), 2754.

Vick SC, et al. (2025) Mucosal tissue NK cells tune their function between optimal anti-pathogen activity and tissue protection. *bioRxiv : the preprint server for biology*.

Choe M, et al. (2025) Preclinical Evaluation of Folate Receptor-? Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma.

Cancer research communications, 5(9), 1701.

Rominger MC, et al. (2025) Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state. Cell reports, 44(10), 116185.

Wilcox-King A, et al. (2025) Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope. NPJ vaccines, 10(1), 185.

McCutcheon KR, et al. (2025) Recurrent Breast Cancer Cells Depend on De novo Pyrimidine Biosynthesis to Suppress Ferroptosis. bioRxiv : the preprint server for biology.

Ramsey EL, et al. (2025) MondoA mediates transcriptional coordination between the MYC network and the integrated stress response in pancreatic ductal adenocarcinoma. bioRxiv : the preprint server for biology.

Choo S, et al. (2025) A rescue fanconi anemia humanized mouse model with endogenous FA mutation and high human hematopoietic stem cell chimerism. Molecular therapy. Methods & clinical development, 33(3), 101528.

Freie B, et al. (2025) MAX inactivation deregulates the MYC network and induces neuroendocrine neoplasia in multiple tissues. Science advances, 11(17), eadt3177.

Garcia NMG, et al. (2025) APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer. Cancer research communications, 5(5), 825.

Shenoy MK, et al. (2025) Breast milk IgG engages the mouse neonatal immune system to instruct responses to gut antigens. Science (New York, N.Y.), 389(6761), eado5294.

Rominger MC, et al. (2024) Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state. bioRxiv : the preprint server for biology.

Frank S, et al. (2024) Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies. bioRxiv : the preprint server for biology.

Freie B, et al. (2024) MAX inactivation deregulates the MYC network and induces neuroendocrine neoplasia in multiple tissues. bioRxiv : the preprint server for biology.

Garcia NMG, et al. (2023) APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancer. bioRxiv : the preprint server for biology.